About: Antecedent Immunosuppressive Therapy for Immune-Mediated Inflammatory Diseases in the Setting of a COVID-19 Outbreak

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Antecedent Immunosuppressive Therapy for Immune-Mediated Inflammatory Diseases in the Setting of a COVID-19 Outbreak Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Antecedent Immunosuppressive Therapy for Immune-Mediated Inflammatory Diseases in the Setting of a COVID-19 Outbreak
Creator	Lim, Henry Adelman, Madeline Buechler, Connor Chapman, Chapman, Stephanie Dimitrion, Peter Kohen, Laurie Robinson, Gabrielle Tisack, Aaron Todter, Todter, Erika Veenstra, Jesse
Source	Elsevier; Medline; PMC
abstract	Abstract Background Finite clinical data and understanding of COVID-19 immunopathology has led to limited, opinion-based recommendations for management of immune-mediated inflammatory disease (IMID) patients on immunosuppressive (IS) therapeutics. Objective Determine if IS therapeutic type impacts COVID-19 risk among IMID patients. Methods We conducted a retrospective cohort analysis of Henry Ford Health System (HFHS) patients tested for COVID-19 between February 1st and April 18th, 2020 treated with IS medication for IMID. Therapeutic class of IS medication, comorbidities, and demographic factors were combined into multivariate models to determine predictors of COVID-19 infection, admission, ventilation, and mortality. Results Of 213 IMID patients, 36.2% tested positive for COVID-19, who had no greater odds of being hospitalized or requiring ventilation relative to the general population. No IS therapeutic worsened the course of disease after multivariate correction, though multi-drug regimens and biologics predicted an increased and decreased rate of hospitalization, respectively, with the latter driven by TNFα inhibitors. Limitations A single-center study somewhat limits generalization to community-based settings. Only patients tested for COVID-19 were analyzed. Conclusion IS therapies for IMIDs are not associated with a significantly greater risk of SARS-CoV-2 or severe sequelae when controlling for other factors, and TNFα inhibitors may decrease odds of severe infection.
has issue date	2020-07-28(xsd:dateTime)
bibo:doi	10.1016/j.jaad.2020.07.089
bibo:pmid	32735965
has license	els-covid
sha1sum (hex)	31d0bd1d22d802171fe1b0f3ec108052588d6e99
schema:url	https://doi.org/10.1016/j.jaad.2020.07.089
resource representing a document's title	Antecedent Immunosuppressive Therapy for Immune-Mediated Inflammatory Diseases in the Setting of a COVID-19 Outbreak
has PubMed Central identifier	PMC7385924
has PubMed identifier	32735965
schema:publication	J Am Acad Dermatol
resource representing a document's body	covid:31d0bd1d22d802171fe1b0f3ec108052588d6e99#body_text
is schema:about of	named entity 'word count' named entity 'word count' named entity 'Antecedent' named entity 'Therapy' named entity 'Immunosuppressive' named entity 'word count' named entity 'word count' named entity 'Immunosuppressive Therapy' named entity 'Immune-Mediated Inflammatory Diseases' named entity 'Immune-Mediated Inflammatory Diseases' named entity 'immunomodulation' named entity 'hydroxychloroquine' named entity 'negative predictor' named entity 'urticaria' named entity 'higher risk' named entity 'DMARD' named entity 'gastrointestinal' named entity 'Henry Ford' named entity 'ventilator' named entity 'COVID' named entity 'biologic therapy' named entity 'Detroit' named entity 'COVID' named entity 'COVID-19' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'chronic liver disease' named entity 'China' named entity 'DMARD' named entity '1.1' named entity 'monotherapy' named entity 'corticosteroid' named entity 'tested positive for COVID-19' named entity 'omalizumab' named entity 'Asymptomatic patients' named entity 'DMARDs' named entity 'logistic regression' named entity 'comorbidities' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'immunosuppressive' named entity 'hydroxychloroquine' named entity 'COVID-19' named entity 'IL-6' named entity 'PCR' named entity 'asymptomatic' named entity 'emergency department' named entity 'odds ratio' named entity 'systemic corticosteroids' named entity 'biologics' named entity 'corticosteroids' named entity 'biologics' named entity 'COVID' named entity 'high-risk' named entity 'endocrine' named entity 'dermatology' named entity 'monotherapy' named entity 'COVID-19' named entity 'epidemiology' named entity 'asymptomatic' named entity 'higher risk' named entity 'uveitis' named entity 'Henry Ford' named entity 'COVID-19' named entity 'coronaviruses' named entity 'IL-1' named entity 'monotherapy' named entity 'ventilator' named entity 'SARS-CoV-2' named entity 'comorbidities'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software